scholarly journals Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation

2016 ◽  
Vol 19 (4) ◽  
pp. 239-249 ◽  
Author(s):  
Samuel G. Smith ◽  
Lucy Side ◽  
Susanne F. Meisel ◽  
Rob Horne ◽  
Jack Cuzick ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Chemoprevention ◽  
Qualitative Investigation ◽  
Breast Cancer Chemoprevention ◽  
The Uk

Spices with Breast Cancer Chemopreventive and Therapeutic Potentials: A Functional Foods Based-Review

2018 ◽  
Vol 18 (2) ◽  
pp. 182-194 ◽  
Author(s):  
Aliyu Muhammad ◽  
Mohammed Auwal Ibrahim ◽  
Ochuko Lucky Erukainure ◽  
Ibrahim Malami ◽  
Auwal Adamu
Keyword(s):  
Breast Cancer ◽  
Urban Areas ◽  
Cancer Chemoprevention ◽  
Biologically Active ◽  
Active Metabolites ◽  
Rural And Urban Areas ◽  
Anticancer Properties ◽  
Rural And Urban ◽  
Breast Cancer Chemoprevention ◽  
Biologically Active Metabolites

Background: Cancer is a multifaceted metabolic disease that affects sizeable dwellers of rural and urban areas. Among the various types of cancer, mammary cancer is one of the most frequently diagnosed cancers in women. Its menace can be curbed with locally consumed spices due to their multiple bioactive phytochemicals. Aims: This review focuses on the breast cancer chemopreventive and therapeutic potentials of locally consumed spices. Methods/Results: The most commonly consumed spices with breast cancer chemopreventive and chemotherapeutic phytochemical include pepper, onions, ginger, garlic, curry and thyme containing many biologically active metabolites ranging from vitamins, fatty acids esters, polyphenols/phenolics, sulfurcontaining compounds and anthraquinones with proven antioxidant, anti-inflammatory, immuno-modulatory, antitumor and anticancer properties against breast cancer/carcinogenesis. Therefore, extracts and active principles of these spices could be explored in breast cancer chemoprevention and possibly therapeutically which may provide an avenue for reducing the risk and prevalence of breast cancer.

Design of multifunctional ethosomes for topical fenretinide delivery and breast cancer chemoprevention

2021 ◽  
pp. 126745
Author(s):  
Alexsandra Conceição Apolinário ◽  
Leon Hauschke ◽  
Jessica Ribeiro Nunes ◽  
Felipe Rebello Lourenço ◽  
Luciana Biagini Lopes
Keyword(s):  
Breast Cancer ◽  
Cancer Chemoprevention ◽  
Breast Cancer Chemoprevention

scholarly journals Addressing Barriers to Uptake of Breast Cancer Chemoprevention for Patients and Providers

2015 ◽  
pp. e50-e58 ◽  
Author(s):  
Katherine D. Crew
Keyword(s):  
Breast Cancer ◽  
Primary Prevention ◽  
High Risk ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Chemoprevention ◽  
The United States ◽  
Cancer Risk Assessment ◽  
Breast Cancer Risk Assessment ◽  
Breast Cancer Chemoprevention

Breast cancer is the most common malignancy among women in the United States, and the primary prevention of this disease is a major public health issue. Because there are relatively few modifiable breast cancer risk factors, pharmacologic interventions with antiestrogens have the potential to significantly affect the primary prevention setting. Breast cancer chemoprevention with selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene, and with aromatase inhibitors (AIs) exemestane and anastrozole, is underutilized despite several randomized controlled trials demonstrating up to a 50% to 65% relative risk reduction in breast cancer incidence among women at high risk. An estimated 10 million women in the United States meet high-risk criteria for breast cancer and are potentially eligible for chemoprevention, but less than 5% of women at high risk who are offered antiestrogens for primary prevention agree to take it. Reasons for low chemoprevention uptake include lack of routine breast cancer risk assessment in primary care, inadequate time for counseling, insufficient knowledge about antiestrogens among patients and providers, and concerns about side effects. Interventions designed to increase chemoprevention uptake, such as decision aids and incorporating breast cancer risk assessment into clinical practice, have met with limited success. Clinicians can help women make informed decisions about chemoprevention by effectively communicating breast cancer risk and enhancing knowledge about the risks and benefits of antiestrogens. Widespread adoption of chemoprevention will require a major paradigm shift in clinical practice for primary care providers (PCPs). However, enhancing uptake and adherence to breast cancer chemoprevention holds promise for reducing the public health burden of this disease.

scholarly journals Breast cancer chemoprevention

2011 ◽  
Vol 2 (4) ◽  
pp. 223
Author(s):  
Ivana Sestak ◽  
Jack Cuzick
Keyword(s):  
Breast Cancer ◽  
Cancer Chemoprevention ◽  
Similar Efficacy ◽  
Breast Cancers ◽  
New Agents ◽  
Breast Cancer Chemoprevention ◽  
Er Positive ◽  
Prevention Trials ◽  
Endometrial Cancers ◽  
Positive Breast Cancer

Trials with tamoxifen have clearly shown that the risk of developing oestrogen receptor positive breast cancer can be reduced by at least 50% with prophylactic agents. The current challenge is to find new agents which achieve this or better efficacy, but with fewer side effects. Recent results indicate that the SERM raloxifene has similar efficacy to tamoxifen, but leads to fewer endometrial cancers, gynecological symptoms, and thromboembolic events. Results for contralateral tumors in adjuvant trials suggest that aromatase inhibitors may be able to prevent up to 70%–80% of ER-positive breast cancers, and this is currently being investigated in two large prevention trials, one using anastrozole (IBIS-II) and the other exemestane (MAP.3). New agents are needed for receptor negative breast cancer and several possibilities are currently under investigation.

Sign in / Sign up

Export Citation Format

Share Document